Study probes what patients and doctors know about NATPARA risks
NCT ID NCT05556629
First seen Jan 25, 2026 · Last updated May 25, 2026 · Updated 23 times
Summary
This study surveyed 200 patients and doctors to check their understanding of the risks and safe use of NATPARA, a drug for hypoparathyroidism. Participants answered true/false questions online, by phone, or on paper. No study medicine was given. The goal was to see how well key safety messages were understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shire-NPS Pharmaceuticals, INC. (Shire now part of Takeda)
Lexington, Massachusetts, United States
Conditions
Explore the condition pages connected to this study.